| Literature DB >> 35972929 |
Robert Hodgson1, Mousumi Biswas2, Stephen Palmer3, David Marshall1, Mark Rodgers1, Lesley Stewart1, Mark Simmonds1, Dheeraj Rai4, Ann Le Couteur5.
Abstract
BACKGROUND: The economic and social costs of autism are significant. This study evaluates the cost-effectiveness of early intensive Applied Behaviour Analysis (ABA)-based interventions for autistic pre-school children in the UK.Entities:
Mesh:
Year: 2022 PMID: 35972929 PMCID: PMC9380934 DOI: 10.1371/journal.pone.0270833
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1Model structure.
Parameter inputs used in the economic analysis.
|
| ||||||
|
|
|
|
|
|
| |
|
| 87.57% | 1.47% | Beta-bionomial | 84.69% | 90.45% | IPD Meta-analysis |
|
| 82.95% | 3.32% | Beta-bionomial | 57.32% | 61.55% | IPD Meta-analysis |
|
| 36 | 0 | NA | NA | NA | Assumption |
|
| 63.19 | 0.43 | Beta-bionomial | 62.35 | 64.04 | IPD Meta-analysis |
|
| 59.43 | 1.08 | Beta-bionomial | 57.32 | 61.55 | IPD Meta-analysis |
|
| 6.98 | 0.18 | Beta-bionomial | 6.63 | 7.33 | IPD Meta-analysis |
|
| ||||||
|
|
|
|
|
|
| |
|
| —0.45 | 1.27 | Normal | -2.94 | 2.04 | [ |
|
| -0.28 | 1.24 | Normal | -2.70 | 2.14 | |
|
| ||||||
|
|
|
|
|
|
| |
|
| 2.92 | 2.46 | Normal | -1.90 | 7.76 | IPD Meta-analysis |
|
| 9.16 | 2.44 | Normal | 4.38 | 13.93 | |
|
| ||||||
|
|
|
|
|
|
| |
|
| 7.00 | 2.58 | Normal | 1.95 | 12.06 | IPD Meta-analysis |
|
| 14.13 | 2.54 | Normal | 9.16 | 19.10 | |
|
| ||||||
|
|
|
|
|
|
| |
|
| -0.08 | 0.02 | Normal | -0.12 | -0.042 | [ |
|
| -.02 | 0.01 | Normal | -0.051 | 0.006 | |
|
| -8.75 | 0.02 | Normal | -11.08 | -6.42 | |
|
| -6.10 | 0.86 | Normal | -7.781 | -4.41 | |
|
| ||||||
|
|
|
|
|
|
| |
|
| -0.04 | 0.02 | Normal | -12.48 | -6.27 | [ |
|
| -0.06 | 0.02 | Normal | -9.32 | -3.89 | |
|
| -9.37 | 1.58 | Normal | -0.084 | -0.001 | |
|
| -6.60 | 1.39 | Normal | -0.089 | -0.025 | |
|
| ||||||
|
|
|
|
|
|
| |
|
| 30% | N/A | N/A | N/A | N/A | [ |
|
| 38% | N/A | N/A | N/A | N/A | |
|
| 32% | N/A | N/A | N/A | N/A | |
|
| 1% | N/A | N/A | N/A | N/A | |
|
| 27% | N/A | N/A | N/A | N/A | |
|
| 72% | N/A | N/A | N/A | N/A | |
|
| ||||||
|
|
|
|
|
|
| |
|
| −0.2438 | 0.2015 | Beta-bionomial | -0.639 | 0.154 | [ |
|
| 0.0119 | 0.0186 | Beta-bionomial | -0.025 | 0.048 | |
|
| 0.0003 | 0.0010 | Beta-bionomial | -0.002 | 0.001 | |
|
| -0.0063 | 0.0078 | Beta-bionomial | 0.0071 | 0.013 | |
|
| 0.0304 | 0.0478 | Beta-bionomial | -0.063 | 0.124 | |
|
| 0.0103 | 0.0016 | Beta-bionomial | -0.021 | 0.009 | |
|
| ||||||
|
|
|
|
|
|
| |
|
| £36,682.78 | £7,336 | Gamma | £22,303 | £51,062 | Micro-costed [ |
|
| £8,634.33 | £1,726 | Gamma | £5,249 | £12,019 | Assumption/personnel communication. |
|
| ||||||
|
|
|
|
|
|
| |
|
| £1,900.09 | £762.41 | Normal | $405. | £3394 | [ |
|
| -£8.78 | £13.98 | Normal | -£36.18 | £18.63 | |
|
| -£7.81 | £10.99 | Normal | -£29.35 | £13.74 | |
|
| ||||||
|
|
|
|
|
|
| |
|
| £4,417.70 | £883 | Gamma | £2,686 | £6,149 | [ |
|
| £8,689.78 | £1,737 | Gamma | £5,283 | £12,096 | |
|
| £15,702.78 | £3,140 | Gamma | £9,547 | £21,858 | |
|
| ||||||
|
|
|
|
|
|
| |
|
| £0.00 | NA | NA | NA | NA | [ |
|
| £53,274.88 | £10,654.98 | Gamma | £32,391 | £74,159 | |
|
| £99,336.44 | £19,867.29 | Gamma | £60,397 | £13,8276 | |
|
| £115,553.00 | £23,110.60 | Gamma | £70,256 | £16,0850 | |
|
| £17,728.57 | £3,545.71 | Gamma | £10,779 | £24,678 | |
|
| £1,927.00 | £385.40 | Gamma | £1,172 | £2,682 | |
|
| £290.00 | £58.00 | Gamma | £176 | £404 | |
|
| £4,159.00 | £831.80 | Gamma | £2529 | 5789.328 | |
|
| £43.00 | £8.60 | Gamma | £26.14 | 59.86 | |
|
| £726.00 | £145.20 | Gamma | £441 | £1,010 | |
ABA = Applied Behaviour Analysis, ADOS = Autism Diagnostic Observation Schedule, IQ = intelligence quotient, SE = Standard error, TAU = Treatment as Usual, VABs = Vineland Adaptive Behavior Scales
* Annual changes in scores
Base-case results (deterministic analysis).
| Scenario | Therapy | Costs | QALYs | Inc. cost | Inc. QALYs | ICER |
|---|---|---|---|---|---|---|
|
| ||||||
|
| ABA | £76,622 | 4.61 | £57,879 | 0.24 | £236,837 |
| TAU | £18,743 | 4.37 | - | - | - | |
|
| ABA | £75,976 | 5.21 | £57,233 | 0.84 | £68,362 |
| TAU | £18,743 | 4.37 | - | - | - | |
|
| ||||||
|
| ABA | £195,310 | 4.61 | £43,940 | 0.24 | £179,799 |
| TAU | £151,370 | 4.37 | - | - | - | |
|
| ABA | £187,612 | 5.21 | £36,242 | 0.84 | £43,289 |
| TAU | £151,370 | 4.37 | - | - | - | |
ABA = Applied Behaviour Analysis, ICER = incremental cost-effectiveness ratio, Inc. = Incremental, QALY = Quality Adjusted Life Years, TAU = Treatment as Usual.
Fig 2Tornado diagram (pessimistic analysis).
Fig 3Tornado diagram (optimistic analysis).
Scenario analysis results: Public sector perspective.
| Scenario | Therapy | Costs | QALYs | Inc. cost | Inc. QALYs | ICER |
|---|---|---|---|---|---|---|
|
| ||||||
|
| ABA | £1,800,040 | 6.87 | £43,940 | 0.24 | £179,799 |
| TAU | £1,756,100 | 6.62 | - | - | - | |
|
| ABA | £1,705,806 | 8.49 | -£50,294 | 1.86 | Dominant |
| TAU | £1,756,100 | 6.62 | - | - | - | |
|
| ||||||
|
| ABA | £170,113 | 4.61 | £12,325 | 0.24 | £50,435 |
| TAU | £157,788 | 4.37 | - | - | - | |
|
| ABA | £169,467 | 5.21 | £11,680 | 0.84 | £13,951 |
| TAU | £157,788 | 4.37 | - | - | - | |
ABA = Applied Behaviour Analysis, ICER = incremental cost-effectiveness ratio, Inc. = Incremental, QALY = Quality Adjusted Life Years, TAU = Treatment as Usual.
*Dominant implies greater benefits at lower costs.
Base-case results: Probabilistic analysis.
| Scenario | Therapy | Costs | QALYs | Inc. cost | Inc. QALYs | ICER |
|---|---|---|---|---|---|---|
|
| ||||||
|
| ABA | £76,587 | 5.02 | £58,940 | 0.24 | £240,868 |
| TAU | £17,648 | 4.77 | - | - | - | |
|
| ABA | £76,341 | 5.60 | £58,630 | 0.85 | £69,385 |
| TAU | £17,711 | 4.75 | - | - | - | |
|
| ||||||
|
| ABA | £191,264 | 5.00 | £46,103 | 0.24 | £189,122 |
| TAU | £145,161 | 4.75 | - | - | - | |
|
| ABA | £184,411 | 5.61 | £39,233 | 0.84 | £46,768 |
| TAU | £145,178 | 4.77 | - | - | - | |
ABA = Applied Behaviour Analysis, ICER = incremental cost-effectiveness ratio, Inc. = Incremental, QALY = Quality Adjusted Life Years, TAU = Treatment as Usual.
Fig 4Cost-effectiveness acceptability curve (CEAC).